B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
(-4.4%)
Cap. Flow
-$860M
Cap. Flow
% of AUM
-25.49%
Top 10 Holdings %
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19
Avg Time Held
1
year
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Transmedics
TMDX
|
+$85.8M |
| 2 |
Keros Therapeutics
KROS
|
+$61.7M |
| 3 |
Legend Biotech
LEGN
|
+$59.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$49.3M |
| 5 |
Geron
GERN
|
+$28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Penumbra
PEN
|
+$40.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$39M |
| 3 |
Arvinas
ARVN
|
+$31.6M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$30.9M |
| 5 |
DexCom
DXCM
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.36% |
| 2 | Miscellaneous | 33.64% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Relay Therapeutics
RLAY
$3.75B
| – | – |
-3,499,427
| Closed | -$24.8M | – |
|
77
SkinHealth Systems
SKIN
$75.5M
| – | – |
-202,485
| Closed | -$5.83M | – |
|
78
DELISTED
Verve Therapeutics
VERV
| – | – |
-623,980
| Closed | -$3.02M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q4 2024 Portfolio in Review
As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.
- Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
- Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
- Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
- Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
- Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
- Braidwell opened 13 new positions and closed 19 in Q4 2024.
- Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.
Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.